Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CYPB - Cypress BioScience -- Ignore unavailable to you. Want to Upgrade?

To: Meridian who wrote (40)	1/14/1998 5:05:00 PM
From: Amigo Mike	Respond to of 586

Brian, >>>>The crucial piece is whether or not this phase III trial will prove anything ... that is in a statistically significant way. Are the results different from zero? Was it double-blind, placebo controlled, lots of centers, big population ... or was it something other than this? I do know that CYPB is/was always in need of cash and financed through Allen and Company every 6-9 months. Were they strapped enough for cash that they scrimped on the trial? If so, we've got some problems. If not we've got a definite winner. <<<<< Your question here has already been answered by the company and in its press releases for the last 6 months. Double Blinded, 12 arthritis centers, over 100 patients. CYPB had no involvment in the data provided from the trial until now. Trial reviewed by independent bureau. Mike